Previous 10 | Next 10 |
Anika Therapeutics, Inc. (ANIK) Q1 2019 Earnings Conference Call May 2, 2019 5:00 PM ET Company Participants Sylvia Cheung – Chief Financial Officer Joseph Darling – President and Chief Executive Officer Conference Call Participants Mike Petusky – Barring...
Anika Therapeutics (NASDAQ: ANIK ): Q1 GAAP EPS of $0.31 beats by $0.11 . More news on: Anika Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total Revenue Increased 16% Year-over-Year Solid Bottom Line Performance with $0.31 Diluted EPS New Leadership Added to Accelerate Innovation and Expand Commercial Reach Announces $50 Million Share Repurchase Program Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, ...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that its Board of Directors has authorized the repurchase of ...
Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S. Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its ...
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday, May 2, 2019, at 5:00 p.m. ET to discuss i...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative medicine and orthobiologics portfolio at...
Industry veteran brings extensive experience leading high-performing R&D groups Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , ...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its innovative commercial and pipeline portfolio at the ...
Anika Therapeutics Inc. (ANIK) Q4 2018 Results Conference Call February 22, 2019 05:00 PM ET Company Participants Sylvia Cheung - Chief Financial Officer Joseph Darling - President and Chief Executive Officer Conference Call Participants Mike Petusky - Barrington Research J...
News, Short Squeeze, Breakout and More Instantly...
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries completed during the limited market release, highlighting the growing interest and commerci...
2024-07-09 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 13:30:02 ET Stephens analyst issues EQUAL-WEIGHT recommendation for ANIK on May 29, 2024 12:00PM ET. The previous analyst recommendation was Equal-Weight. ANIK was trading at $25.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...